Key factors
sym | PALI |
exch | US |
MCap | 6044.95K |
Beta | 1.46 |
EPS | -27.0 |
Div date | 0000-00-00 |
Yesterday
sym | PALI |
exch | US |
close | 7.74 |
50 Day MA | 5.737 |
200 Day MA | 9.769 |
52 Week High | 36.6 |
52 Week Low | 3.82 |
Target Price | 33.75 |
Market Cap Mln | 6.044 |
Share statistics
Shares Outstanding | 851.40K |
Shares Float | 836.47K |
Percent Institutions | 15.52 |
PercentInsiders | 1.753 |
SharesShort | 34516 |
Short Ratio | 0.5 |
Shares Short Prior Month | 27421 |
Short Percent | 4.749 |
Short Percent Float | 4.749 |
Income
Revenue TTM | 250.0K |
Revenue Per Share TTM | 0.548 |
EBITDA | -12.8M |
Diluted Eps TTM | -27.0 |
earning
Operating Margin TTM | -51.3 |
EPS Estimate Current Quarter | -0.34 |
EPS Estimate Current Year | -14.3 |
EPS Estimate Next Quarter | -0.32 |
EPS Estimate Next Year | -11.8 |
Earnings Share | -27.0 |
Dividend
Dividend Date | 2019-07-18 |
Last Split Date | 2024-04-08 |
Last Split Factor | 1:15 |
business
Enterprise Value Ebitda | 0.696 |
Enterprise Value Revenue | 234.88 |
Book Value /share | 18.30 |
Price Book MRQ | 0.310 |
Price Sales TTM | 14.03 |
ReturnOnAssetsTTM | -0.53 |
ReturnOnEquityTTM | -1.03 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US6963891055 |
CIK | 1357459 |
Code | PALI |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-05-03 |
info
Fiscal Year End | December |
Full Time Employees | 9.0 |
IPODate | 2006-12-20 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Palisade Bio Inc |
Address | 7750 El Camino Real, Carlsbad, CA, United States, 92009 |
Country Name | USA |
Phone | 858 704 4900 |
Web URL | https://www.palisadebio.com |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.